VFEND IV (voriconazole), triazole antifungal

VFEND has been reassessed in curative treatment of:

-          invasive aspergillosis and serious fungal infections with Scedosporium spp. or Fusarium spp., where it retains its major therapeutic contribution as the standard treatment.

-          for invasive candidiasis and candidemia, where it offers few advantages relative to fluconazole: fungistatic activity comparable to that of fluconazole, less sensitivity for C. glabrata with reduced fluconazole sensitivity and increased cross resistance among azole derivatives. It is mainly recommended as an oral relay treatment in candidiasis with C. krusei and C. glabrata sensitive to voriconazole.